Compare
Oric Pharmaceuticals, Inc. vs Alumis Inc. vs Nkarta, Inc. vs Stoke Therapeutics, Inc.
| Latest fiscal year | Oric Pharmaceuticals, Inc. ORIC | Alumis Inc. ALMS | Nkarta, Inc. NKTX | Stoke Therapeutics, Inc. STOK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $24.05M | $0 | $184.42M |
| Revenue growth (YoY) | n/a | n/a | n/a | +404.5% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | -11.2% |
| Net margin | n/a | n/m | n/a | -3.7% |
| Net income | -$129.47M | -$243.32M | -$104.08M | -$6.88M |
| EPS (Diluted) | -$1.47 | -$2.86 | -$1.41 | -$0.12 |
| Operating cash flow | -$110.97M | -$369.52M | -$88.70M | $45.59M |
| Free cash flow | -$111.68M | -$370.18M | -$89.91M | $44.91M |
| Cash & equivalents | $45.67M | $89.67M | $39.63M | $84.22M |
| Total assets | $408.89M | $411.94M | $404.21M | $418.43M |
| Total liabilities | $24.53M | $110.64M | $91.88M | $65.98M |
| Shareholders' equity | $384.36M | $301.30M | $312.32M | $352.46M |
| Return on year-end equity | -33.7% | -80.8% | -33.3% | -2.0% |
| Shares outstanding | 98.53M | n/a | 71.08M | 58.92M |
Revenue, most recent five fiscal years
| Fiscal year | Oric Pharmaceuticals, Inc. | Alumis Inc. | Nkarta, Inc. | Stoke Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $24.05M Ended 2025-12-31 | $0 Ended 2025-12-31 | $184.42M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $0 Ended 2024-12-31 | $36.55M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $8.78M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $12.40M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | n/a |